Activation of complement during apheresis.
C3 activation products and the terminal complement complex (TCC) were examined in plasma during plasmapheresis of patients with Guillain-Barré Syndrome (GBS) (n = 4), Waldenström's syndrome (n = 4), and hypercholesterolaemia (n = 1), or during cytapheresis of platelet (n = 10) and granulocyte (n = 2) donors. Blood specimens were taken before, during and after the procedures. There was a significant activation of complement after apheresis in the GBS patients and one of the patients with Waldenström's syndrome, but not in the other patients. There were no significant differences in complement activation products before compared with after cytapheresis in the healthy donors. This demonstrates the biocompatibility with respect to complement activation of the materials used. The observed complement activation in some of the patients during plasma exchange is probably caused by activation products in the replacement plasma.
Hetland
G
G
Department of Immunology, Ullevaal Hospital, Oslo, Norway.
Mollnes
T E
TE
Garred
P
P
D003167:Complement Activation; D003176:Complement C3 / Q000378:metabolism; D016238:Cytapheresis; D006801:Humans; D010956:Plasmapheresis; D011129:Polyradiculoneuropathy / Q000276:immunology; D008258:Waldenstrom Macroglobulinemia / Q000276:immunology
D003176:Complement C3